These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28919755)

  • 1. Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma.
    Kuai R; Subramanian C; White PT; Timmermann BN; Moon JJ; Cohen MS; Schwendeman A
    Int J Nanomedicine; 2017; 12():6581-6594. PubMed ID: 28919755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer.
    Wang T; Subramanian C; Yu M; White PT; Kuai R; Sanchez J; Moon JJ; Timmermann BN; Schwendeman A; Cohen MS
    Surgery; 2019 Dec; 166(6):1168-1175. PubMed ID: 31371177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas.
    Subramanian C; Kuai R; Zhu Q; White P; Moon JJ; Schwendeman A; Cohen MS
    Surgery; 2016 Jan; 159(1):284-94. PubMed ID: 26582501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II promotes selective uptake of high density lipoprotein cholesterol esters in bovine adrenal glomerulosa and human adrenocortical carcinoma cells through induction of scavenger receptor class B type I.
    Cherradi N; Bideau M; Arnaudeau S; Demaurex N; James RW; Azhar S; Capponi AM
    Endocrinology; 2001 Oct; 142(10):4540-9. PubMed ID: 11564720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins.
    Fawaz MV; Kim SY; Li D; Ming R; Xia Z; Olsen K; Pogozheva ID; Tesmer JJG; Schwendeman A
    J Pharmacol Exp Ther; 2020 Feb; 372(2):193-204. PubMed ID: 31776208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of apolipoprotein A-I peptide phospholipid interaction and its effect on HDL nanodisc assembly.
    Patel H; Ding B; Ernst K; Shen L; Yuan W; Tang J; Drake LR; Kang J; Li Y; Chen Z; Schwendeman A
    Int J Nanomedicine; 2019; 14():3069-3086. PubMed ID: 31118623
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting.
    Tang J; Kuai R; Yuan W; Drake L; Moon JJ; Schwendeman A
    Nanomedicine; 2017 Aug; 13(6):1869-1878. PubMed ID: 28434931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy.
    Gong M; Zhang Q; Zhao Q; Zheng J; Li Y; Wang S; Yuan Y
    Drug Deliv; 2019 Dec; 26(1):708-716. PubMed ID: 31290708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
    Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
    Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
    Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
    Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization.
    Tang J; Li D; Drake L; Yuan W; Deschaine S; Morin EE; Ackermann R; Olsen K; Smith DE; Schwendeman A
    J Lipid Res; 2017 Jan; 58(1):124-136. PubMed ID: 27881716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
    Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
    Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin.
    Yuan Y; Wen J; Tang J; Kan Q; Ackermann R; Olsen K; Schwendeman A
    Int J Nanomedicine; 2016; 11():6229-6238. PubMed ID: 27920529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of Lipid Nanodisks Containing Apolipoprotein E-Derived Synthetic Peptides for Biocompatible Delivery Vehicles Targeting Low-Density Lipoprotein Receptor.
    Tanaka M; Hasegawa M; Yoshimoto N; Hoshikawa K; Mukai T
    Biol Pharm Bull; 2019; 42(8):1376-1383. PubMed ID: 31366872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
    Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
    Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
    Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
    Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study.
    Wu L; Huang X; Kuang Y; Xing Z; Deng X; Luo Z
    Drug Des Devel Ther; 2019; 13():2787-2798. PubMed ID: 31496655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics.
    Li D; Fawaz MV; Morin EE; Ming R; Sviridov D; Tang J; Ackermann R; Olsen K; Remaley AT; Schwendeman A
    Mol Pharm; 2018 Jan; 15(1):83-96. PubMed ID: 29141139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.
    Fiorentini C; Fragni M; Perego P; Vezzoli S; Bonini SA; Tortoreto M; Galli D; Claps M; Tiberio GA; Terzolo M; Missale C; Memo M; Procopio G; Zaffaroni N; Berruti A; Sigala S
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4594-4602. PubMed ID: 27626976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo.
    Cheng Y; Kerppola RE; Kerppola TK
    Endocr Relat Cancer; 2016 Apr; 23(4):1-19. PubMed ID: 26843528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.